Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149759 · ClinicalTrials.gov registry record · NA
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
A NA study of Atopic Dermatitis and Eczema, sponsored by Rockefeller University.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01149759 is a NA study of Atopic Dermatitis and Eczema that has completed, run by Rockefeller University. The registered enrollment target is 9 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01149759, a NA study of Atopic Dermatitis and Eczema, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States. Patients with severe AD will be studied during a 24-week study with systemic cyclosporine (Neoral, capsule form) to evaluate the immune suppression and pathological correlation of cyclosporine A in these patients in order to determine the extent to which immune activation drives the pathological epidermal phenotype.
Conditions Studied
Interventions
- DRUG Cyclosporine A
Study Locations (1)
New York
- The Rockefeller University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01149759
The ClinicalTrials.gov registry entry for NCT01149759 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (99% lower). The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Cyclosporine A is the first listed.
NCT01149759 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01149759 about?
NCT01149759 is a clinical study titled "Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy". Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States. Patients with severe AD will be studied during a 24-week study with systemic cyclosporine (Neoral, capsule form) to evaluate the immune sup...
What is the current status of trial NCT01149759?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2010-06. Estimated completion is 2014-12.
What conditions does trial NCT01149759 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT01149759?
The interventions under investigation include: Cyclosporine A (DRUG).
Who is sponsoring clinical trial NCT01149759?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01149759 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
RECRUITING · NA
-
Topical Treatment for Atopic Dermatitis
RECRUITING · NA
-
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
COMPLETED · NA
-
A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
COMPLETED · NA
-
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
COMPLETED · NA
-
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.